CA3215826A1 - Use of chlorophyll derivatives for the treatment of sars-cov-2 infection - Google Patents

Use of chlorophyll derivatives for the treatment of sars-cov-2 infection Download PDF

Info

Publication number
CA3215826A1
CA3215826A1 CA3215826A CA3215826A CA3215826A1 CA 3215826 A1 CA3215826 A1 CA 3215826A1 CA 3215826 A CA3215826 A CA 3215826A CA 3215826 A CA3215826 A CA 3215826A CA 3215826 A1 CA3215826 A1 CA 3215826A1
Authority
CA
Canada
Prior art keywords
pheophorbide
analog
acceptable salt
pharmaceutically acceptable
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3215826A
Other languages
English (en)
French (fr)
Inventor
Jonathan ZUCCOLO
Amir J. ZUCCOLO
Jimmy D. DIKEAKOS
Corby FINK
Gregory A. Dekaban
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affinityimmuno Inc
Original Assignee
Affinityimmuno Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affinityimmuno Inc filed Critical Affinityimmuno Inc
Publication of CA3215826A1 publication Critical patent/CA3215826A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
CA3215826A 2021-05-05 2022-05-04 Use of chlorophyll derivatives for the treatment of sars-cov-2 infection Pending CA3215826A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163201568P 2021-05-05 2021-05-05
US63/201,568 2021-05-05
PCT/CA2022/050697 WO2022232930A1 (en) 2021-05-05 2022-05-04 Use of chlorophyll derivatives for the treatment of sars-cov-2 infection

Publications (1)

Publication Number Publication Date
CA3215826A1 true CA3215826A1 (en) 2022-11-10

Family

ID=83931896

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3215826A Pending CA3215826A1 (en) 2021-05-05 2022-05-04 Use of chlorophyll derivatives for the treatment of sars-cov-2 infection

Country Status (5)

Country Link
US (1) US20240366564A1 (cg-RX-API-DMAC7.html)
EP (1) EP4333839A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024516712A (cg-RX-API-DMAC7.html)
CA (1) CA3215826A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022232930A1 (cg-RX-API-DMAC7.html)

Also Published As

Publication number Publication date
WO2022232930A1 (en) 2022-11-10
US20240366564A1 (en) 2024-11-07
EP4333839A4 (en) 2025-03-19
EP4333839A1 (en) 2024-03-13
JP2024516712A (ja) 2024-04-16

Similar Documents

Publication Publication Date Title
JP2008523153A (ja) 疾病の伝染を減少させる組成物及び方法
US20150166476A1 (en) Methods for treating neurodegenerative diseases associated with aggregation of amyloid-beta
AU2009347566B2 (en) A novel standardized composition, method of manufacture and use in the resolution of RNA virus infection
EP3046558B1 (en) Deoxynojirimycin derivatives and methods of their using
GB2644651A (en) Methods for the prophylaxis and treatment of COVID and COVID-19
US20220304976A1 (en) Method of simultaneously treating viral disease caused coronavirus, its variants and mutants using a pharmaceutical micronutrient composition
Hao et al. Kaempferol is a novel antiviral agent against channel catfish virus infection through blocking viral attachment and penetration in vitro
Azarkar et al. Curcumin as a natural potential drug candidate against important zoonotic viruses and prions: A narrative review
Kim et al. Anti‐Influenza Activity of an Ethyl Acetate Fraction of a Rhus verniciflua Ethanol Extract by Neuraminidase Inhibition
US20240366564A1 (en) Use of Chlorophyll Derivatives for the Treatment of SARS-CoV-2 Infection
US9221874B2 (en) Antiviral peptides against influenza virus
US20240100047A1 (en) Composition and method for treating covid-19
EP4164597A1 (en) Methylene blue and riboflavin for prophylactic and therapeutic anti-viral therapy
US8530525B2 (en) Methods and compositions for protecting and treating neuroinjury
Ben-Azu et al. Amelioration of chronic unpredictable mild Stress-Induced behavioural perturbations by noni juice in mice: possible involvement of antioxidant system
WO2022248564A1 (en) Compositions for treating sars-cov2 infection
CN116942733A (zh) 一种草药萃取物用于制备抑制个体感染新型冠状病毒的医药组合物的用途
US20240307487A1 (en) Compositions of anti-viral peptides and/or compounds and methods of use thereof
US20230390235A1 (en) Therapeutic agent for covid-19
US20160243182A1 (en) Use of cissampelos pareira extracts for treating dengue
EA050727B1 (ru) Антивирусный препарат микробного происхождения, обладающий активностью в отношении вирусов гриппа и коронавирусов
WO2022123513A1 (en) Composition and method for managing coronavirus infection
WO2023244471A1 (en) Compositions and methods for radioprotectant/radiomitigation hybrid and/or decorporation
EP4376864A1 (en) Therapeutic formulations from pelargonium sp. and method of use in respiratory viral infections
KR20170039456A (ko) 오동나무로부터 추출한 c-제라닐플라보노이드계 물질을 포함하는 인플루엔자 예방 및 치료용 약학 조성물

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250328

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250328

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260615

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260625